These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 11234874)

  • 1. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
    Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
    Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
    Villalona-Calero MA; Eckhardt SG; Weiss G; Hidalgo M; Beijnen JH; van Kesteren C; Rosing H; Campbell E; Kraynak M; Lopez-Lazaro L; Guzman C; Von Hoff DD; Jimeno J; Rowinsky EK
    Clin Cancer Res; 2002 Jan; 8(1):75-85. PubMed ID: 11801542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
    van Kesteren C; Cvitkovic E; Taamma A; López-Lázaro L; Jimeno JM; Guzman C; Math t RA; Schellens JH; Misset JL; Brain E; Hillebrand MJ; Rosing H; Beijnen JH
    Clin Cancer Res; 2000 Dec; 6(12):4725-32. PubMed ID: 11156226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
    Lau L; Supko JG; Blaney S; Hershon L; Seibel N; Krailo M; Qu W; Malkin D; Jimeno J; Bernstein M; Baruchel S
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):672-7. PubMed ID: 15701855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
    Taamma A; Misset JL; Riofrio M; Guzman C; Brain E; Lopez Lazaro L; Rosing H; Jimeno JM; Cvitkovic E
    J Clin Oncol; 2001 Mar; 19(5):1256-65. PubMed ID: 11230466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
    Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
    Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
    van Kesteren C; Twelves C; Bowman A; Hoekman K; López-Lázaro L; Jimeno J; Guzman C; Mathôt RA; Simpson A; Vermorken JB; Smyth J; Schellens JH; Hillebrand MJ; Rosing H; Beijnen JH
    Anticancer Drugs; 2002 Apr; 13(4):381-93. PubMed ID: 11984084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
    Puchalski TA; Ryan DP; Garcia-Carbonero R; Demetri GD; Butkiewicz L; Harmon D; Seiden MV; Maki RG; Lopez-Lazaro L; Jimeno J; Guzman C; Supko JG
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):309-19. PubMed ID: 12357306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
    Ryan DP; Puchalski T; Supko JG; Harmon D; Maki R; Garcia-Carbonero R; Kuhlman C; Winkelman J; Merriam P; Quigley T; Jimeno J; Manola J; Demetri GD
    Oncologist; 2002; 7(6):531-8. PubMed ID: 12490740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ET-743: the French experience.
    Brain EG
    Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
    Garcia-Carbonero R; Supko JG; Maki RG; Manola J; Ryan DP; Harmon D; Puchalski TA; Goss G; Seiden MV; Waxman A; Quigley MT; Lopez T; Sancho MA; Jimeno J; Guzman C; Demetri GD
    J Clin Oncol; 2005 Aug; 23(24):5484-92. PubMed ID: 16110008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
    Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
    J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
    Laverdiere C; Kolb EA; Supko JG; Gorlick R; Meyers PA; Maki RG; Wexler L; Demetri GD; Healey JH; Huvos AG; Goorin AM; Bagatell R; Ruiz-Casado A; Guzman C; Jimeno J; Harmon D
    Cancer; 2003 Aug; 98(4):832-40. PubMed ID: 12910529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
    Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
    Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
    Yovine A; Riofrio M; Blay JY; Brain E; Alexandre J; Kahatt C; Taamma A; Jimeno J; Martin C; Salhi Y; Cvitkovic E; Misset JL
    J Clin Oncol; 2004 Mar; 22(5):890-9. PubMed ID: 14990645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.